S. 3794: Safeguarding Americans from Fraudulent and Experimental Drugs Act of 2026

This bill, known as the Safeguarding Americans from Fraudulent and Experimental Drugs Act of 2026, proposes to amend existing regulations regarding compounding pharmacies and outsourcing facilities under the Federal Food, Drug, and Cosmetic Act. Below are the key components of the bill:

Regulation of Compounding Pharmacies

The bill introduces stricter rules on how compounding pharmacies can operate. Specifically:

• Pharmacies are limited to compounding a drug that is nearly identical to a commercially available drug no more than 20 times in a single month.
• It defines what constitutes an "essentially a copy" of a commercially available drug. This includes any drug that has the same active ingredients and does not provide a significant improvement for an individual patient.

Reporting Requirements

Pharmacies and facilities that exceed the threshold for compounding drugs for patients outside their state must submit annual reports. These reports will include:

• The types of compounded drug products they provided.
• The number of times each type of drug product was compounded.

This reporting will help monitor compliance with safety standards and limit unnecessary compounding of drugs.

Inspections of Outsourcing Facilities

The bill mandates more frequent inspections of large-scale outsourcing facilities, which are defined as those compounding more than 100 products per year. The requirements include:

• Inspections before the facility compounds any drug product for the first time.
• Reinspections at least every two years.

Registration and Reporting for Large-Scale Facilities

It specifies that certain exemptions from registration will not apply to outsourcing facilities, ensuring that these facilities are subjected to the same regulatory standards as others.

Fee Adjustments

The bill also changes the base establishment fee for activities related to ensuring the safety of compounded drug products. The exact amount will be determined by the Secretary of Health and Human Services, replacing the previous fixed fee of $15,000.

Implementation Timeline

The new regulations resulting from this bill would begin to take effect six months after the bill is enacted.

Relevant Companies

• PFE (Pfizer Inc.) - Pfizer could be impacted by changes in competition from compounding pharmacies that are now more tightly regulated.
• MRK (Merck & Co., Inc.) - Similar to Pfizer, Merck might see changes in its market for specific drugs that are compounded.
• ABBV (AbbVie Inc.) - AbbVie may face implications concerning its drugs that are targeted by compounded alternatives.